Please login to the form below

Not currently logged in
Email:
Password:

EU approves Janssen's prostate cancer drug

The European Commission has approved Janssen-Cilag's Zytiga, a treatment for metastatic castration-resistant prostate cancer (mCRPC)

Janssen-Cilag has announced that the European Commission (EC) has approved its late stage prostate cancer drug Zytiga (abiraterone acetate) for marketing. The approval follows an accelerated regulatory review process by the European Medicines Agency (EMA) and a positive opinion from the Committee for Medicinal Products for Human Use (CHMP).

Zytiga is a novel, once-daily, oral, androgen biosynthesis inhibitor, which when combined with prednisone or prednisolone, acts as a treatment for metastatic castration-resistant prostate cancer (mCRPC) in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

Professor Karim Fizazi, Department of Cancer Medicine, Institute Gustave Roussy, France, commented that Zytiga "gives new hope to men who are suffering from this late stage of prostate cancer" and that it helps them "live longer with a better quality of life and less pain."

8th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

Star’s a full service resourcing house and for almost 12 years we’ve recruited the best people for pharma, medical devices...

Latest intelligence

14_ipad_lowres.jpg
Do your customers feel that you’re listening to them?
When answering to data, excellent digital communication can create much stronger relationships between reps and customers....
Mapping content strategies to pharma lifecycle management
In these tough economic times, we should be ramping up our pharma lifecycle management (LCM) strategies. These are well-established strategies for managing and extending the commercial value of products. So...
Back from the future – innovation for pharma
After 5 days of seeing amazing innovations, having discussions about the future of medicine and the practicalities of living on Mars. Plus listening to inspiring speakers from fighter plane-flying physicians...

Infographics